全球非小細胞肺癌 (NSCLC) 治療市場(2022-2027 年):行業趨勢-COVID-19 的影響-公司分析
市場調查報告書
商品編碼
1066773

全球非小細胞肺癌 (NSCLC) 治療市場(2022-2027 年):行業趨勢-COVID-19 的影響-公司分析

Non-Small Cell Lung Cancer Treatment (NSCLC) Market, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Company Analysis

出版日期: | 出版商: Renub Research | 英文 175 Pages | 商品交期: 最快1-2個工作天內

價格

在 2021 年的預測期內,全球非小細胞肺癌 (NSCLC) 治療市場預計將以 6.4% 的複合年增長率增長,到 2027 年將達到 257.1 億美元。它一直在增長。

NSCLC 在所有人群和年齡組中的發病率都在增加,對 NSCLC 治療的需求也在增加。在發達國家和新興國家,NSCLC 診斷數量的增加和意識的提高也推動了市場的增長。此外,吸煙者比例的增加和接觸石棉等有害物質也有助於市場的擴大。

本報告探討了非小細胞肺癌 (NSCLC) 治療的全球市場、市場概況、影響市場增長的因素分析、市場規模趨勢/預測、組織學/治療類型/藥物類別。總結了最終用戶和地區、主要公司概況等類別。

目錄

第一章介紹

第2章調查/調查方法

第 3 章執行摘要

第四章市場動態

  • 生長因子
  • 挑戰

第五章非小細胞肺癌(NSCLC)治療市場

第6章市場份額分析:非小細胞肺癌(NSCLC)的治療

  • 按組織類型
  • 按治療類型
  • 按藥物類別
  • 最終用戶
  • 按地區

第 7 章非小細胞肺癌 (NSCLC) 治療市場:按組織學類型分類

  • 腺癌
  • 鱗狀細胞癌
  • 大細胞癌

第 8 章非小細胞肺癌 (NSCLC) 治療市場:按治療類型分類

  • 化療
  • 免疫療法
  • 放射治療
  • 手術
  • 靶向治療劑

第 9 章非小細胞肺癌 (NSCLC) 治療市場:按藥物分類

  • 血管生成抑製劑
  • 表皮生長因子受體阻滯劑
  • 激□抑製劑
  • 微管穩定劑
  • 葉酸抗代謝物
  • PD-1/PD-L1抑製劑

第 10 章非小細胞肺癌 (NSCLC) 治療市場:按最終用戶分類

  • 綜合內科/外科醫院
  • 專科醫院
  • 診所
  • 其他

第 11 章非小細胞肺癌 (NSCLC) 治療市場:按地區劃分

  • 北美
  • 歐洲
  • 亞太地區
  • 其他領域

第12章搬運工五力分析

第13章主要公司

  • AbbVie Inc.
  • Astellas Pharma
  • AstraZeneca
  • Avid Bioservices Inc.
  • Bayer Healthcare
  • Biogen Inc.
  • Blueprint Medicines Corp
  • Eli Lilly and Company
  • Merck & co Inc.
  • Novartis
  • Pfizer Inc.

Global Non-Small Cell Lung Cancer (NSCLC) Market will reach US$ 25.71 Billion in 2027. Globally, lung cancer is one of the most frequent types of cancer, with two distinct subtypes. The non-small cell lung cancer subtype accounts for most lung cancer cases (NSCLC). Furthermore, lung cancer, as one of the most common malignancies in the world, is responsible for a considerable number of deaths globally. As a result of the expanding frequency and incidence of non-small cell lung cancer across all demographics and age categories, demand for non-small cell lung cancer therapies has increased.

COVID-19 Impact on Non-Small Cell Lung Cancer Treatment (NSCLC) Industry:

Non-Small Cell Lung Cancer Treatment (NSCLC) Market represented a central challenge in clinical diagnosis and therapy decision-making in the context of the favorably contagious COVID-19 pandemic. Even for patients who were non-COVID-19, the disturbance of regular hospital services, such as imaging and treatment appointments, had a significant impact on the physical and mental well-being of these patients. The stress placed on the availability of medical resources and hospitals has reduced the clinical admissions to most other departments, including oncology departments. Consequently, the benefits some cancer patients could have received have been compromised due to treatment delay declining the market in 2020.

Worldwide Non-Small Cell Lung Cancer (NSCLC) Market Size has reached US$ 17.75 Billion in 2021

The rise of the non-small cell lung cancer therapy (NSCLC) market has been fuelled by the increased number of non-small cell lung cancer diagnoses and increased awareness in developed and emerging countries. Other reasons contributing to the expansion of the non-small cell lung cancer treatments market include an increase in the proportion of smokers and exposure to toxins such as asbestos. According to our estimates, the Non-Small Cell Lung Cancer (NSCLC) Market will grow at a 6.4% CAGR from 2021 to 2027.

Adenocarcinoma Is the Most Prevalent Segment Histologically:

Our report classified the histological segment into three categories: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Compared to the other two forms, adenocarcinoma is the most common and is found in the cells responsible for mucous secretion in the outer lung sections. Furthermore, Squamous Cell Carcinoma, located in the squamous cells near the bronchus in the middle of the lungs, is one of the fastest expanding segments in the market. Large cell carcinoma, also known as undifferentiated carcinoma, can develop in any section of the lungs, is the fastest-growing, and is the most difficult to cure.

Immunotherapy Market Share is Estimated to Be the Largest:

By treatment, immunotherapy is expected to have the most significant market share. According to our estimates, the targeted therapy category will grow during the projection period. The increasing number of product launches, particularly in the immunotherapy area, is credited with the market domination. Immunotherapy is currently being used more widely in emerging countries, owing to improved patient outcomes resulting from effective treatment.

Regional Analysis:

In our report, we have examined the regions like North America, Europe, Asia-Pacific, Rest of The World. Lung cancer is becoming more common, and innovative therapies and are becoming more widely used, making the North America, Europe & Asia Pacific the most powerful region worldwide. Due to a rise in lung cancer diagnoses, India and China in the Asia Pacific region are seeing growth in NSCLC therapies. Chemotherapy is the most common kind of treatment in these underdeveloped countries. However, advanced immunotherapies and targeted medicines are seeing rising adoption and investment in nations like United States, Germany, United Kingdom, and Japan.

Key Market Players:

Our report examines AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company, Merck & Co Inc., Novartis, and Pfizer Inc. as leading players in the Non-Small Cell Lung Cancer Treatment (NSCLC) Market. The majority of significant market players are also concentrating on continuous advancements in advanced therapies and improving the efficacy of existing medicines. These businesses are receiving product approvals as well.

Renub Research latest report "Non-Small Cell Lung Cancer Treatment (NSCLC) Market, Global Forecast By Histology Type (Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma), Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy Drugs), Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, PD-1/ PD-L1 Inhibitor), End User (General Medical & Surgical Hospitals, Specialty Hospitals, Clinics, Others), Region (North America, Europe, Asia-Pacific, Rest of The World), Companies (AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company, Merck & co Inc., Novartis, Pfizer Inc.)" provides a detailed analysis of Non-Small Cell Lung Cancer Treatment (NSCLC) Industry.

Histology Type - Market has been covered from 3 viewpoints:

  • 1. Adenocarcinoma
  • 2. Squamous Cell Carcinoma
  • 3. Large Cell Carcinoma

Treatment Type - Market has been covered from 5 viewpoints:

  • 1. Chemotherapy
  • 2. Immunotherapy
  • 3. Radiation Therapy
  • 4. Surgery
  • 5. Targeted Therapy Drugs

Drug Class - Market has been covered from 6 viewpoints:

  • 1. Angiogenesis Inhibitor
  • 2. Epidermal Growth Factor Receptor Blocker
  • 3. Kinase Inhibitor
  • 4. Microtubule Stabilizer
  • 5. Folate Antimetabolites
  • 6. PD-1/ PD-L1 Inhibitor

End User - Market has been covered from 4 viewpoints:

  • 1. General Medical & Surgical Hospitals
  • 2. Specialty Hospitals
  • 3. Clinics
  • 4. Others

Region - Market has been covered from 4 viewpoints:

  • 1. North America
  • 2. Europe
  • 3. Asia-Pacific
  • 4. Rest of The World

Company Insights:

  • Overview
  • Recent Development
  • Revenue

Key Players:

  • 1. AbbVie Inc.
  • 2. Astellas Pharma
  • 3. AstraZeneca
  • 4. Avid Bioservices Inc.
  • 5. Bayer Healthcare
  • 6. Biogen Inc.
  • 7. Blueprint Medicines Corp
  • 8. Eli Lilly and Company
  • 9. Merck & co Inc.
  • 10. Novartis
  • 11. Pfizer Inc.

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Non-Small Cell Lung Cancer Treatment (NSCLC) Market

6. Market Share Analysis - Non-Small Cell Lung Cancer Treatment (NSCLC)

  • 6.1 By Histology Type
  • 6.2 By Treatment Type
  • 6.3 By Drug Class
  • 6.4 By End User
  • 6.5 By Region

7. Histology Type - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

  • 7.1 Adenocarcinoma
  • 7.2 Squamous Cell Carcinoma
  • 7.3 Large Cell Carcinoma

8. Treatment Type - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

  • 8.1 Chemotherapy
  • 8.2 Immunotherapy
  • 8.3 Radiation Therapy
  • 8.4 Surgery
  • 8.5 Targeted Therapy Drugs

9. Drug Class - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

  • 9.1 Angiogenesis Inhibitor
  • 9.2 Epidermal Growth Factor Receptor Blocker
  • 9.3 Kinase Inhibitor
  • 9.4 Microtubule Stabilizer
  • 9.5 Folate Antimetabolites
  • 9.6 PD-1/ PD-L1 Inhibitor

10. End User - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

  • 10.1 General Medical & Surgical Hospitals
  • 10.2 Specialty Hospitals
  • 10.3 Clinics
  • 10.4 Others

11. Region - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

  • 11.1 North America
  • 11.2 Europe
  • 11.3 Asia-Pacific
  • 11.4 Rest of The World

12. Porters Five Forces

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13. Key Players

  • 13.1 AbbVie Inc.
    • 13.1.1 Overview
    • 13.1.2 Recent Development
    • 13.1.3 Revenue
  • 13.2 Astellas Pharma
    • 13.2.1 Overview
    • 13.2.2 Recent Development
    • 13.2.3 Revenue
  • 13.3 AstraZeneca
    • 13.3.1 Overview
    • 13.3.2 Recent Development
    • 13.3.3 Revenue
  • 13.4 Avid Bioservices Inc.
    • 13.4.1 Overview
    • 13.4.2 Recent Development
    • 13.4.3 Revenue
  • 13.5 Bayer Healthcare
    • 13.5.1 Overview
    • 13.5.2 Recent Development
    • 13.5.3 Revenue
  • 13.6 Biogen Inc.
    • 13.6.1 Overview
    • 13.6.2 Recent Development
    • 13.6.3 Revenue
  • 13.7 Blueprint Medicines Corp
    • 13.7.1 Overview
    • 13.7.2 Recent Development
    • 13.7.3 Revenue
  • 13.8 Eli Lilly and Company
    • 13.8.1 Overview
    • 13.8.2 Recent Development
    • 13.8.3 Revenue
  • 13.9 Merck & co Inc.
    • 13.9.1 Overview
    • 13.9.2 Recent Development
    • 13.9.3 Revenue
  • 13.10 Novartis
    • 13.10.1 Overview
    • 13.10.2 Recent Development
    • 13.10.3 Revenue
  • 13.11 Pfizer Inc.
    • 13.11.1 Overview
    • 13.11.2 Recent Development
    • 13.11.3 Revenue

List of Figures

  • Figure-01: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Billion US$), 2016 - 2021
  • Figure-02: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Billion US$), 2022 - 2027
  • Figure-03: Histology Type - Adenocarcinoma Market (Million US$), 2016 - 2021
  • Figure-04: Histology Type - Forecast for Adenocarcinoma Market (Million US$), 2022 - 2027
  • Figure-05: Histology Type - Squamous Cell Carcinoma Market (Million US$), 2016 - 2021
  • Figure-06: Histology Type - Forecast for Squamous Cell Carcinoma Market (Million US$), 2022 - 2027
  • Figure-07: Histology Type - Large Cell Carcinoma Market (Million US$), 2016 - 2021
  • Figure-08: Histology Type - Forecast for Large Cell Carcinoma Market (Million US$), 2022 - 2027
  • Figure-09: Treatment Type - Chemotherapy Market (Million US$), 2016 - 2021
  • Figure-10: Treatment Type - Forecast for Chemotherapy Market (Million US$), 2022 - 2027
  • Figure-11: Treatment Type - Immunotherapy Market (Million US$), 2016 - 2021
  • Figure-12: Treatment Type - Forecast for Immunotherapy Market (Million US$), 2022 - 2027
  • Figure-13: Treatment Type - Radiation Therapy Market (Million US$), 2016 - 2021
  • Figure-14: Treatment Type - Forecast for Radiation Therapy Market (Million US$), 2022 - 2027
  • Figure-15: Treatment Type - Surgery Market (Million US$), 2016 - 2021
  • Figure-16: Treatment Type - Forecast for Surgery Market (Million US$), 2022 - 2027
  • Figure-17: Treatment Type - Targeted Therapy Drugs Market (Million US$), 2016 - 2021
  • Figure-18: Treatment Type - Forecast for Targeted Therapy Drugs Market (Million US$), 2022 - 2027
  • Figure-19: Drug Class - Angiogenesis Inhibitor Market (Million US$), 2016 - 2021
  • Figure-20: Drug Class - Forecast for Angiogenesis Inhibitor Market (Million US$), 2022 - 2027
  • Figure-21: Drug Class - Epidermal Growth Factor Receptor Blocker Market (Million US$), 2016 - 2021
  • Figure-22: Drug Class - Forecast for Epidermal Growth Factor Receptor Blocker Market (Million US$), 2022 - 2027
  • Figure-23: Drug Class - Kinase Inhibitor Market (Million US$), 2016 - 2021
  • Figure-24: Drug Class - Forecast for Kinase Inhibitor Market (Million US$), 2022 - 2027
  • Figure-25: Drug Class - Microtubule Stabilizer Market (Million US$), 2016 - 2021
  • Figure-26: Drug Class - Forecast for Microtubule Stabilizer Market (Million US$), 2022 - 2027
  • Figure-27: Drug Class - Folate Antimetabolites Market (Million US$), 2016 - 2021
  • Figure-28: Drug Class - Forecast for Folate Antimetabolites Market (Million US$), 2022 - 2027
  • Figure-29: Drug Class - PD-1/ PD-L1 Inhibitor Market (Million US$), 2016 - 2021
  • Figure-30: Drug Class - Forecast for PD-1/ PD-L1 Inhibitor Market (Million US$), 2022 - 2027
  • Figure-31: End User - General Medical & Surgical Hospitals Market (Million US$), 2016 - 2021
  • Figure-32: End User - Forecast for General Medical & Surgical Hospitals Market (Million US$), 2022 - 2027
  • Figure-33: End User - Specialty Hospitals Market (Million US$), 2016 - 2021
  • Figure-34: End User - Forecast for Specialty Hospitals Market (Million US$), 2022 - 2027
  • Figure-35: End User - Clinics Market (Million US$), 2016 - 2021
  • Figure-36: End User - Forecast for Clinics Market (Million US$), 2022 - 2027
  • Figure-37: End User - Others Market (Million US$), 2016 - 2021
  • Figure-38: End User - Forecast for Others Market (Million US$), 2022 - 2027
  • Figure-39: North America - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 - 2021
  • Figure-40: North America - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 - 2027
  • Figure-41: Europe - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 - 2021
  • Figure-42: Europe - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 - 2027
  • Figure-43: Asia-Pacific - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 - 2021
  • Figure-44: Asia-Pacific - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 - 2027
  • Figure-45: Rest of the World - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 - 2021
  • Figure-46: Rest of the World - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 - 2027
  • Figure-47: AbbVie Inc. - Global Revenue (Million US$), 2016 - 2021
  • Figure-48: AbbVie Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-49: Astellas Pharma - Global Revenue (Million US$), 2016 - 2021
  • Figure-50: Astellas Pharma - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-51: AstraZeneca - Global Revenue (Million US$), 2016 - 2021
  • Figure-52: AstraZeneca - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-53: Avid Bioservices Inc. - Global Revenue (Million US$), 2016 - 2021
  • Figure-54: Avid Bioservices Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-55: Bayer Healthcare - Global Revenue (Million US$), 2016 - 2021
  • Figure-56: Bayer Healthcare - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-57: Biogen Inc. - Global Revenue (Million US$), 2016 - 2021
  • Figure-58: Biogen Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-59: Blueprint Medicines Corp - Global Revenue (Million US$), 2016 - 2021
  • Figure-60: Blueprint Medicines Corp - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-61: Eli Lilly and Company - Global Revenue (Million US$), 2016 - 2021
  • Figure-62: Eli Lilly and Company - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-63: Merck & co Inc. - Global Revenue (Million US$), 2016 - 2021
  • Figure-64: Merck & co Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-65: Novartis - Global Revenue (Million US$), 2016 - 2021
  • Figure-66: Novartis - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-67: Pfizer Inc. - Global Revenue (Million US$), 2016 - 2021
  • Figure-68: Pfizer Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027

List of Tables

  • Table-01: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Histology Type (Percent), 2016 - 2021
  • Table-02: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Histology Type (Percent), 2022 - 2027
  • Table-03: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Treatment Type (Percent), 2016 - 2021
  • Table-04: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Treatment Type (Percent), 2022 - 2027
  • Table-05: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Drug Class (Percent), 2016 - 2021
  • Table-06: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Drug Class (Percent), 2022 - 2027
  • Table-07: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by End-User (Percent), 2016 - 2021
  • Table-08: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by End-User (Percent), 2022 - 2027
  • Table-09: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (Percent), 2016 - 2021
  • Table-10: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (Percent), 2022 - 2027